INTRODUCTION
Ukrain (Tris(2-([5bS-(5ba,6b,12ba)]-5b,6,7,12b,13, 14-hexahydro-13-methyl [1, 3] benzodioxolo [5,6-v (celandine) conjugated with thiophosphoric acid. 1 It has immunoregulatory effects on T lymphocyte subsets 2 and is reported to exert cytotoxic and cytostatic effects on various malignant cells. 3 The mechanism of action of Ukrain remains uncertain. Exposure of cancer cell lines to this compound results in growth inhibition concomitant with cell cycle arrest in G 2 /M. This inhibition is associated with altered expression of mitotic cyclins A and B1 and of cyclin-dependent kinases CDK1 and CDK2 and the CDK inhibitor p27 is upregulated. 4 Panzer et al. found that Ukrain inhibits tubulin polymerization, leading to impaired microtubule dynamics, resulting in activation of the spindle checkpoint and thus a metaphase block. 5 In addition, Ukrain has been found to decrease the synthesis of DNA, RNA and proteins, 6 and to inhibit cellular oxygen consumption. 7 Ukrain can induce apoptosis in cancer cells in vitro 4, 8, 9 and in vivo 10 by a mechanism independent of changes in bcl-2 or bax expression. 9 There are two characterized signal pathways leading to apoptosis: the death receptor and the mitochondrial pathway. Both are orchestrated by the activation of caspases, a family of conserved proteases that cleave crucial cellular substrates. The mitochondrial pathway is characterized by the release of mitochondrial cytochrome c to the cytosol where, together with the adapter protein APAF-1 and procaspase 9, it assembles the apoptosome, a multiprotein complex. 11 This complex induces the activation of caspase 9, which cleaves and activates downstream caspases that cleave a broad spectrum of cellular targets, resulting in the typical apoptotic morphology. Caspases are in turn regulated by a conserved group of cellular inhibitors, the Inhibitors of Apoptosis Proteins (IAPs). 12 The IAPs must be downregulated or inhibited to allow activated caspases to cleave their substrates. 13 A key component of steady-state IAP regulation is the transcription factor NF-κ B. 14 This important regulator induces the transcription of several antiapoptotic factors including XIAP, IAP-1 and IAP-2. 15 NF-κ B is commonly upregulated in cancer cells, 16, 17 so several attempts are currently underway to block its activation in order to render cells more susceptible to antineoplasic treatments. 16, [18] [19] [20] [21] More recently, a proapoptotic role for NF-κ B has been demonstrated in various models, through the upregulation of death receptors such as CD95L, TNF and TRAIL and of transcriptional factors such as p53 and c-myc. 22, 23 Although it has been reported that Ukrain induces alterations in the cell cycle and tubulin polymerization, the specific cellular target has not been identified. Since antineoplasic agents induce NF-κ B 24 and their effects are regulated by this transcription factor, 25 we investigated the participation of NF-κ B in the apoptotic effects of Ukrain.
MATERIALS AND METHODS
Cell lines and culture. Cell lines were obtained from the American Type Culture Collection (ATCC). Cells were maintained as a monolayer at 37˚C and cultured in Dulbecco's modified Eagle medium containing 8% (v/v) fetal bovine serum in a humidified atmosphere with 5% (v/v) carbon dioxide in air. In order to generate a transgenic cell line defective in the canonical NF-κ pathway, we transfected HeLa cells with plasmid vectors containing a wild type or a dominant-negative Iκ-B (mutated at serine 32 and 36), kindly provided by P. Baeuerle. The S32/36 mutation prevents ubiquitination and degradation of Iκ-B protein and, thus blocks the activation of NF-κ B. Cells were then selected and analyzed (see below). Cells were thereafter termed HeKB (wild type Iκ-B) and HeKS32 (Iκ-B mutated at S32/36). To generate cells in which the pathway is constitutively activated, HeLa cells were transfected with a plasmid vector containing the IKK2 sequence; it has previously been shown that overexpression of this kinase induces constitutive activation. 26 To generate stable cell lines, cultures were selected with G418 for 4 weeks. Cells were thereafter referred as HeIKK. In order to avoid clonal variation, six clones were pooled and tested for transgene expression and NF-κ B responsiveness. In order to obtain a cell line defective in Bcl-3, we transfected HEK293 cells with a plasmid (pSIREN, Clontech) containing the sequence for producing a double stranded 23 base pair siRNA directed against Bcl-3, under the control of an U6 promoter. After selection and screening, retroviral supernatants were collected, titrated and stored in liquid nitrogen. To generate the HeBcl3-cell line, ten million HeLa cells were infected at a multiplicity of infection of 1 x 10 7 , selected for 4 weeks with G418, cloned and six clones pooled. All cell culture reagents were obtained from Invitrogen (Frederick, MD).
Cellular viability and cytotoxic effects. Cells were seeded in 24 chamber dishes at the density described and exposed to several concentrations of Ukrain for 24 or 48 hours. The concentrations used to determine the IC 50 ranged from 1 to 100 µg/ml. For the rest of the experiments, the IC 50 value at 48 hours was used (40 µg/ml). The cells were then fixed in 70% ethanol at -20˚C, washed in PBS and stained with crystal violet (1% in water). After washing, the stain was solubilized in 33% acetic acid and the absorbance was determined in an ELISA reader at 570 nm. Clonogenic assays were performed as reported previously. 27 The analyses were performed at least in triplicate in four independent experiments. Nuclear staining. Cells were fixed with cold ethanol at 70% for 15 min and pretreated with RNAse (10 µg/ml) in PBS for 30 min at 37˚C. The nuclei were stained with ethidium bromide (5 µg/ml) in PBS and washed twice with PBS. Finally, the cells were visualized with a Zeiss microscope using epifluorescence and photographed with a digital camera (Nikkon 4500).
Western blot analysis. Cells were washed with ice-cold phosphatebuffered saline and total extracts were prepared by lysis in 500 µl of Laemmli buffer, sonication for 20 seconds and centrifugation at 8000 x g for 30 minutes at 4˚C. Equal amounts of protein were separated and electrophoresed on an 8-15% SDS-polyacrylamide gel (PAGE). After transferring to a PVDF membrane (AmershamPharmacia, UK) and blocking in nonfat milk for 1 hour, the blot was incubated with monoclonal or monospecific polyclonal antibodies against caspases 8, 9 and 3, IκB α, Bcl3 and actin (Santa Cruz Biotechnology, CA, USA). After washing, the blots were reincubated for 2 hours with a mouse or anti-rabbit IgG-HRP antibody (AmershamPharmacia, UK). Antibody binding was determined using enhanced chemiluminiscence (Amersham-Pharmacia, UK) with X-Omat AR films (Kodak, México). 28 Gene reporter analyses. To measure NF-κ B activity, we established a HeLa cell line derivative (hereafter termed HeNFR) in which the plasmids pNF-kB-Luc and pBK-CMV (Stratagene CA) were cotransfected using lipofectamine 2000 (Invitrogen, MD) in a 10:1 ratio, selected for 4 weeks in G418 (Invitrogen, MD), cloned and pooled. HeNFR cells were tested for linear activation of the reporter and reproducibility using H 2 O 2 and TNF-α exposure (not shown). The cells were exposed to Ukrain for the times described and NF-κ B activity was analyzed by the luciferase assay system (Promega, WI), using a microplate luminometer as described by the manufacturer. All experiments were performed in triplicate in three independent experiments.
Statistical analysis. Data are expressed as means ± SD from at least three independent experiments performed by triplicate. A Student's t test was used to compare individual data with control value. For western blot densitometric analyses, a Bonferroni t test was used. A probability of p < 0.05 was taken as denoting a significant difference from control data.
RESULTS
To determine whether Ukrain induces apoptosis in cancer cells, we exposed HeLa cells to several concentrations (1 to 100 µg/ml) of the compound for 24 or 48 hours. As shown in Figure 1 , Ukrain induced a marked dose and time-dependent decrease of viability. To examine the generality of this effect, we tested several other cancer cell lines (Fig. 1 , and other data not shown). Sensitivity to Ukrain, defined as the relative decrease of cellular viability, varied among cell lines, from an IC 50 of 43 ± 6 µg/ml in HeLa cells to 78 ± 9 µg/ml in SW480 colon cancer cells. Interestingly, nontransformed fibroblasts (hTERT cell line) were insensitive to the drug. The cytotoxic effect of Ukrain on sensitive cell lines depended on cell confluence, suggesting that it might be modulated by the cell cycle or cell-cell contact (Fig. 1) . Unexpectedly, clonogenic assays using different doses of Ukrain for less than 24 hours failed to show a reproducible death effect on several cancer cell lines (Fig. 2) , indicating a requirement for long time exposure to the drug. To determine whether the decrease of viability in cells exposed to Ukrain for 48 hours was due to apoptosis, we analyzed cellular and nuclear morphology using a fluorescent assay. Figure 3 illustrates the cytosolic condensation, membrane convolution and nuclear condensation and fragmentation seen in cells exposed to Ukrain, typical of apoptotic cell death. Similar results were found in all the cell lines analyzed (not shown).
During apoptosis, cell death is executed by the cleavage-dependent activation of caspases. Caspases comprise two distinct classes, the initiators and the effectors. Initiator caspases 8 and 10 mediate death factor-mediated or extrinsic apoptosis, whereas caspase 9 mediates intrinsic or mitochondria-regulated apoptosis. 12 To identify the mechanism of apoptosis induced by Ukrain, we performed western blot analyses of caspases 8 and 9 and the effector caspase 3 in HeLa cells exposed to the drug. Figure 4 shows that Ukrain induced cleavage of the caspase 9 precursor, with a concomitant increase in effector caspase 3 protein and cleavage of its proform. As expected in view of the previously-reported dependence of antineoplasic agents on the intrinsic cell death pathway, 29 NF-κ B is a pleiotropic transcription factor with a crucial and complex regulatory role in apoptosis. It mediates an antiapoptotic signal in response to a wide range of stimuli, including chemotherapeutic drugs. 24, 25 Depending on the cellular context, this signaling can either impair the response to the death stimuli or be superseded by death signaling. Paradoxically, recent reports show that NF-κ B can also induce apoptosis in certain cells by inducing the extrinsic death pathway. 22 To assess the importance of this cascade in our model, we used a gene reporter assay to determine the rate of NF-κ B transcription in cells exposed to Ukrain. Figure 5 shows that the drug induced NF-κ B activation, as indicated by the increased enzymatic activity of the reporter protein, secreted alkaline phosphatase. To test whether NF-κ B activation modulated the cellular response to Ukrain, we created four transgenic HeLa cell lines. HeKS32 expresses a dominant negative version of Iκ B α and is thus unable to activate the canonical NF-κ B pathway; HeKB overexpresses a wild type Iκ-B α protein; HeBcl3-is a stable derivative with defective Bcl-3, a positive modulator of the noncanonical NF-κ B pathway; and finally, HeIKK cells overexpress IKK2, the main activating kinase of the canonical NF-κ B pathway. 30 When these cells were exposed to Ukrain, we found that blocking the canonical (e.g., HeKS32 and HeKB) or non canonical (e.g., HeBcl3-) NF-κ B transduction pathways did not increase the cytotoxic effects of the drug (Fig. 6) , as would be expected from previous reports in which classical antineoplasic agents were used. 25 In agreement with these results, we found that the opposite approach, that is, activating the NF-κ B cascade by IKK2 overexpression, did not change the response to the drug (Fig. 6 ). All these results show that, even when NF-κ B is activated after Ukrain exposure, this transduction pathway neither participates nor modulates the cytotoxic response to the drug.
DISCUSSION
Ukrain is a novel semi-synthetic compound that has received attention because of its possible use as an effective cancer drug. 31 Nevertheless, its mechanism of action remains elusive. Initially, changes in oxygen consumption were found, 32 along with a requirement for the metabolic redox chain, but no direct cause-effect relationship was shown between these changes and the cytotoxic effects. Liepins 8 reported that Ukrain induces two modes of cell death in K562 leukemia cells, one compatible with apoptosis and the second with mitotic crisis. The induction of apoptosis by Ukrain in vitro has been further demonstrated in Chinese Hamster Ovary cells, 33 prostate cells 9 and epidermoid cancer cells, including vulvar and cervical. 4 Reduction in DNA, RNA and protein synthesis and inhibition of tubulin polymerization have been observed after exposure to Ukrain, 6, 34 but no direct relationship between these cellular effects and cytotoxicity has been demonstrated. In the present paper we found that Ukrain induced apoptosis in cervical, colonic and kidney cancer cells, but not in a nontransformed cell line derived from human fibroblasts. The effect required long exposure to the compound, since the clonogenic sensitivity assays required more than 24 hours in culture to show reproducible death. This accords with the report of Panzer et al., 35 who found that the antimitotic effects of Ukrain were reversible. Although the exact reason for this phenomenon is currently unknown, the doubling time of the HeLa cell line (22 ± 0.2 hours in our laboratory) and confluence-dependent modulation of the effect of Ukrain (Fig. 1 ) could indicate a cell cycle requirement for the action of the drug.
As expected in view of reports on other antineoplasic drugs, 19 apoptosis induced by Ukrain was mediated by the intrinsic pathway, as demonstrated by the cleavage of caspases 9 and 3. This is also supported by the data of Roublevskaia et al., 36 who demonstrated that overexpression of Bcl-2, a regulator of the mitochondrial pathway, impaired responsiveness to Ukrain.
Alterations in tubulin polymerization by antineoplasic drugs usually involve the participation of the extrinsic pathway, as exemplified by paclitaxel, an anticancer compound that also targets microtubules. This drug induces the death receptor (DR)-mediated apoptotic pathway in HeLa cells, involving TRAIL-dependent activation of caspase-8, as well as the mitochondrial-mediated pathway. 37 Since we found no activation of caspase 8, participation of the extrinsic pathway in our model is excluded. Although further investigation is necessary, our results could indicate a secondary role for tubulin as the main target for Ukrain, as suggested by others. 34 NF-κ B is a pleiotropic transcription factor that modulates cellular processes such as proliferation and cell death in response to external and internal stimuli such as cytokines and growth factors, inflammation and stress. It is one of the most important antiapoptotic factors, as demonstrated by the embryonic lethality induced by massive liver apoptosis in knockout mice deficient in the RelA component of NF-κ B. 38 This effect is mediated by direct upregulation of several proteins that inactivate caspases (IAPs), block mitochondrial release of apoptogenic factors (Bcl-2 family members) or displace caspase 8 from the death-inducing signalling complex (FLIP and isoforms). Recently, it has been shown that NF-κ B regulates not only antiapoptotic signals but also proapoptotic signals through the regulation of death receptors and death receptor ligands such as CD95L, TNF and TRAIL (for a review see Ref. 23 ) This further complexity in the regulation of apoptosis by NF-κ B probably depends on additional cross-talking cellular factors that allow for specific spatial and temporal outcomes in multicellular organisms. 39 Indeed, it has been shown that transcription factors such as Sp1 40 and TAF(II)105 41 can bind to the same promoter site as, or interact directly with, NF-κ B, regulating its specificity and activity. In view of the previously reported immunomodulatory effects of Ukrain 2, 42 and the fact that NF-κ B plays a very important role in innate and adaptive immunity, 43 we reasoned that this factor could be mediating or at least regulating the response to Ukrain in cancer cells. In the present report, we show for the first time that even when Ukrain activates NF-κ B, this activation does not modify the drug response. This follows from the observation that neither blockage of canonical NF-κ B, which relies on Iκ-B degradation and the release of prototypic p50/p65 homodimers, nor the depletion of bcl-3, which is required for the transactivation activities of noncanonical p50 and p52 homo or heterodimers, inhibited the action of Ukrain. In support of these data, constitutive activation of the canonical pathway, induced by overexpression of its main activator, IKK2, 30 did not change the responsiveness to the drug. These novel results showing the activation of NF-κ B, along with recent reports demonstrating the immunoregulatory effects of Ukrain on T lymphocyte subsets and on the antitumor effect of NK cells, 2, 42 provide new grounds for investigating whether NF-κ B regulation could also be responsible for the immunomodulatory effects of Ukrain.
In conclusion, we have shown that Ukrain induces apoptosis in cancer cells by activating the intrinsic death pathway by a mechanism that does not depend on the activation of NF-κ B. Figure 6 . Effect of NF-κB inhibition on cytotoxic effects of Ukrain. (A) HeLa cell line, or stable HeLa derivative HeBcl3-, which expresses a siRNA for Bcl-3; HeKB, expressing I-κB; HeKS32, which expresses an I-κB negative dominant; and HeIKK, which overexpresses IKK2; were exposed to the IC 50 of Ukrain for 48 hours and viability was assessed as described in Material and Methods. Experiments were performed in triplicate in three independent assays. The bars represent standard deviations. 
